Cue Biopharma - CUE Net Assets per Single Share

Public company logo of Cue Biopharma, Inc. (CUE)

Cue Biopharma, Inc. (CUE) management is transparently developing the Immuno-STAT platform while requiring non-dilutive capital. The key book value metric reflects net asset dynamics, where 0.44 represents the current level of the metric. A strong team of immunologists is motivated by high bonuses, and medium-term catalysts are tied to clinical trial data, with R&D expenses already priced in.

cuebiopharma.com (CUE) Equity per Share: for the period 07/04/2022 - 10/28/2026

cuebiopharma.com - analytical breakdowns and key metrics (CUE)

- price and consensus price forecast:
Stock Price Cue Biopharma, Inc.|CUE - Average Forecast Price
- market capitalization data:
Market Value Cue Biopharma, Inc.|CUE - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Cue Biopharma|CUE - Accounting Capitalization|Market Capitalization to Book Value Ratio cuebiopharma.com|CUE - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Cue Biopharma, Inc.|CUE - Long-Term Liabilities to Capital|Short-Term Debt to Equity Cue Biopharma|CUE - Company Debts|Debt to Book Capitalization Ratio Cue Biopharma, Inc.
Fundamental company valuation:Cue Biopharma, Inc., CUE
Finished products of Cue Biopharma

Cue Biopharma, Inc. (CUE) develops innovative cancer drugs within a protected US macro environment where geopolitical risks are minimal. This specific context is reflected in the calculation of net equity per share, which allows for an assessment of the issuer's real asset value and its solvency by analyzing book value per share to determine long-term growth potential.

Competitors of Cue Biopharma, Inc. (CUE)

IBRX (ImmunityBio Corp) - Book Value per Share|IMCR: Net Asset Value per Share|Net Assets per Single Share JANX|RCUS (arcusbio.com) - Net Asset Value per Share|Net Assets per Single Share Zymeworks (ZYME)|Equity per Share Tango Therapeutics Inc|Book Value per Share IOVA (Iovance)|Accounting Value per Share IMTX (Immatics Biotechnologies)|XNCR: Net Assets per Single Share|compasstherapeutics.com - Net Asset Value per Share|REPL - Net Assets per Single Share|LYEL: Net Assets per Single Share|Net Assets per Single Share IPHA|Pyxis Oncology (PYXS) - Net Asset Value per Share|Compugen Ltd - Book Value per Share|Book Value of One Share iobiotech.com (IOBT)|Sutro Biopharma - Accounting Value per Share|Net Asset Value per Share MiNK Therapeutics Inc. INKT|Accounting Value per Share Werewolf Therapeutics, Inc.|Accounting Value of a Share Immix Biopharma Inc. IMMX|Book Value per Share ALXO (ALX Oncology Holdings)|PDSB: Net Assets per Share|SONN (sonnetbio.com) - Net Assets per Single Share|MAIA (MAIA Biotech) - Accounting Value per Share|Net Assets per Single Share LIMN|Accounting Value per Share Lava Tx (LVTX)|Accounting Value per Share NXTC|Book Value per Share LPTX (leaptx.com)|INTS - Net Assets per Single Share|Sensei Biotherapeutics Inc - Equity per Share|TOVX (Synthetic Biologics) - Net Assets per Single Share|Gritstone bio, Inc. (GRTS) - Net Asset Value per Share|Accounting Value per Share KA (Kineta, Inc.)|Book Value of One Share neximmune.com|Turnstone Biologics Corp (TSBX) - Accounting Value per Share|Book Price of a Share Vaccinex Inc.|Harpoon Tx (HARP) - Book Value per Share